IMPACT BIOMEDICAL Enters Material Definitive Agreement
Ticker: IBO · Form: 8-K · Filed: Jan 22, 2024 · CIK: 1834105
| Field | Detail |
|---|---|
| Company | Impact Biomedical Inc. (IBO) |
| Form Type | 8-K |
| Filed Date | Jan 22, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $12,000,000, $12,859,328, $126,380 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: material-agreement, corporate-action
TL;DR
**IMPACT BIOMEDICAL just signed a big deal, watch for details on what it means for their future.**
AI Summary
IMPACT BIOMEDICAL INC. filed an 8-K on January 22, 2024, reporting a material definitive agreement entered into on January 18, 2024. This filing indicates a significant new commitment or partnership for the company, which could impact its future operations and financial performance. For investors, this matters because such agreements often signal strategic shifts, potential revenue streams, or new liabilities, directly influencing the stock's perceived value and future trajectory.
Why It Matters
This filing signals a new, significant business commitment for IMPACT BIOMEDICAL INC., which could lead to new opportunities or obligations that affect its financial health and stock performance.
Risk Assessment
Risk Level: medium — The filing indicates a material agreement without disclosing its specifics, creating uncertainty about its potential positive or negative impact.
Analyst Insight
Investors should await further disclosures from IMPACT BIOMEDICAL INC. regarding the specifics of the material definitive agreement to assess its potential impact on the company's financials and future prospects before making any investment decisions.
Key Players & Entities
- IMPACT BIOMEDICAL INC. (company) — the registrant filing the 8-K
- January 18, 2024 (date) — date of the earliest event reported (entry into material definitive agreement)
- January 22, 2024 (date) — date the 8-K was filed
- Nevada (company) — state of incorporation for IMPACT BIOMEDICAL INC.
- 1400 Broadfield Blvd., Suite 130 Houston, TX 77084 (company) — principal executive offices of IMPACT BIOMEDICAL INC.
Forward-Looking Statements
- IMPACT BIOMEDICAL INC. will release further details about the material definitive agreement. (IMPACT BIOMEDICAL INC.) — high confidence, target: Q1 2024
- The material definitive agreement will involve a strategic partnership or collaboration. (IMPACT BIOMEDICAL INC.) — medium confidence, target: N/A
FAQ
What was the specific date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 18, 2024, which was the date IMPACT BIOMEDICAL INC. entered into a material definitive agreement.
What type of agreement did IMPACT BIOMEDICAL INC. report entering into?
IMPACT BIOMEDICAL INC. reported entering into a "Material Definitive Agreement" as per Item 1.01 of the 8-K filing.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on January 22, 2024, as indicated by the 'FILED AS OF DATE' in the filing header.
What is the business address of IMPACT BIOMEDICAL INC. as stated in the filing?
The business address of IMPACT BIOMEDICAL INC. is 1400 Broadfield Blvd., Suite 130, Houston, TX 77084, with a business phone number of (585) 325-3610.
What is the state of incorporation for IMPACT BIOMEDICAL INC.?
IMPACT BIOMEDICAL INC. is incorporated in Nevada, as stated under 'State or other jurisdiction of incorporation' in the filing.
Filing Stats: 954 words · 4 min read · ~3 pages · Grade level 12.3 · Accepted 2024-01-22 17:12:05
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share N/A N/A Indic
- $12,000,000 — aned Impact an original amount of up to $12,000,000 (the "Loan"). Pursuant to the amendme
- $12,859,328 — ringing the funded principal balance to $12,859,328.60, (iii) eliminate any advance feature
- $126,380 — ng August 31, 2030, Impact will pay DSS $126,380.80, being comprised of both principal a
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex10-1.htm (EX-10.1) — 87KB
- ex10-1_001.jpg (GRAPHIC) — 9KB
- ex10-1_002.jpg (GRAPHIC) — 11KB
- ex10-1_003.jpg (GRAPHIC) — 3KB
- 0001493152-24-003318.txt ( ) — 347KB
- impb-20240118.xsd (EX-101.SCH) — 3KB
- impb-20240118_lab.xml (EX-101.LAB) — 33KB
- impb-20240118_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. IMPACT BIOMEDICAL INC. Date: January 22, 2024 By: /s/ Frank D. Heuszel Name: Frank D. Heuszel Title: Chief Executive Officer